Form 4: PALI CMO Granted 7.6M Restricted Stock Units

Palisade Bio's Chief Medical Officer, Mitchell Lawrence Jones, was granted 7.6 million Restricted Stock Units, vesting over approximately two years.

Summary

• Chief Medical Officer Mitchell Lawrence Jones of Palisade Bio, Inc. (PALI) was granted 7,665,800 Restricted Stock Units (RSUs) on October 6, 2025.
• Each RSU represents a contingent right to receive one share of the company's common stock.
• The RSUs will vest in installments: 1/3rd of the shares on October 6, 2026, and the remaining portion quarterly thereafter over the subsequent eight quarters.
• Vesting is contingent upon Mr. Jones' continuous service to the company through each vesting date.
• The RSUs may be settled in cash if the company does not have sufficient shares reserved under its 2021 Equity Incentive Plan to issue upon settlement.

Sentiment

Score: 7

Explanation: The grant of a significant number of Restricted Stock Units to a key executive is generally positive, as it aligns management's long-term interests with shareholder value and promotes retention. The vesting schedule encourages sustained performance. The only minor concern is the contingency for cash settlement if the equity plan lacks sufficient shares, which could impact cash flow or lead to dilution.

Positives

• The grant of 7,665,800 Restricted Stock Units aligns the Chief Medical Officer's long-term interests with shareholder value.
• The multi-year vesting schedule encourages the retention of key management personnel, ensuring continuity in leadership and strategic execution.

Negatives

• There is a potential for cash settlement of RSUs if the company's 2021 Equity Incentive Plan lacks sufficient reserved shares, which could impact cash flow.
• If new shares are issued to settle the RSUs, it could lead to dilution for existing shareholders.

Risks

• Potential for dilution of existing shareholders if new shares are issued to settle the 7,665,800 RSUs.
• Impact on company cash flow if the RSUs are settled in cash due to insufficient shares reserved under the 2021 Equity Incentive Plan.
• The value of the RSUs is directly tied to the future performance of Palisade Bio's common stock, exposing the executive and indirectly the company to market fluctuations.

Future Outlook

The grant of Restricted Stock Units with a multi-year vesting schedule signifies a long-term commitment to the Chief Medical Officer and aims to align his incentives with the company's future performance and strategic objectives.

Management Comments

• The company has granted 7,665,800 Restricted Stock Units to its Chief Medical Officer, Mitchell Lawrence Jones, as part of its equity incentive program.
• The vesting schedule is designed to ensure continuous service and align executive interests with long-term shareholder value.

Industry Context

Equity grants, such as Restricted Stock Units, are a standard compensation practice within the biotechnology and pharmaceutical industries. These grants are crucial for attracting and retaining highly skilled executives, particularly in R&D-intensive roles like Chief Medical Officer, where long-term project development cycles necessitate sustained commitment.

Comparison to Industry Standards

• The utilization of Restricted Stock Units (RSUs) for executive compensation is a common practice across the biotechnology and pharmaceutical sectors, mirroring strategies employed by companies like Moderna or Pfizer to incentivize long-term performance and executive retention.
• The multi-year vesting schedule, spanning approximately 2.5 years, is typical for executive equity grants and is comparable to vesting periods observed at peer companies for similar leadership roles.
• The size of the grant (7.6 million RSUs) should be assessed relative to Palisade Bio's current market capitalization and total outstanding shares to determine its potential dilutive impact compared to industry benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for long-term value creation through aligned executive incentives; minor potential for dilution if new shares are issued for settlement or impact on cash flow if settled in cash.
• Employees (specifically CMO): Increased long-term compensation and incentive to remain with the company, fostering stability in key leadership.

Next Steps

• Continued service of the Chief Medical Officer to meet the specified vesting conditions for the Restricted Stock Units.
• Future settlement of the vested Restricted Stock Units into common stock or cash on the designated vesting dates.

Key Dates

Recommendation

The grant of a substantial number of Restricted Stock Units to the Chief Medical Officer is a standard executive compensation practice aimed at aligning interests and retaining key talent. While generally positive for long-term alignment, it does not fundamentally alter the company's operational or financial outlook in the short term. Investors should hold and monitor the company's progress, particularly in its clinical development programs, as the value of these RSUs is directly tied to the company's future stock performance. The potential for cash settlement or dilution is a minor consideration but not a primary driver for a strong buy or sell recommendation based solely on this filing.

Keywords

Palisade Bio, PALI, Restricted Stock Units, RSU, Executive Compensation, Insider Ownership, Mitchell Lawrence Jones, Chief Medical Officer, Equity Incentive Plan